Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023
19 Sep, 2014, 16:21 BST
DUBLIN, Sept. 19, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" report to their offering.
For the purposes of this report, the human microbiome market is segmented by application, disease, product, and geography.
The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023. The market is driven by growing incidences of unhealthy lifestyle diseases, and increase in occurrence of autoimmune disorders. However, government regulation and lack of detailed research may restrain the growth of this market to an extent. Investing in probiotic and prebiotic products, medical foods, drugs, and devices will prove fruitful for companies in the future.
The applications segment is further subdivided into therapeutics and diagnostics. Therapeutics may be the leading segment, owing to growing population and diseases.
Currently, the diagnostics segment has fewer products in the pipeline than the therapeutics segment.
The disease market is subdivided into the obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders and others segments. Of these, obesity and acute diarrhea are expected to be the leading segments; acute diarrhea is expected to show the fastest growth . This growth will driven by the rise in lifestyle diseases, aging population and high adoption rates of approved products.
The products segment is subdivided into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Growth in these segments will be majorly driven due to use of probiotics and prebiotics for maintaining gut flora to avoid lifestyle diseases.
The geographic analysis reveals that Europe will account for the largest share within the forecast period of 2019 to 2023, due to high acceptance of probiotic and prebiotic produtcs. Asia is expected to be a profitable region for the human microbiome market and poised to grow at a healthy CAGR in the forecast period. North America will show a low market share; however, it is expected to grow at a high CAGR from 2019 to 2023.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. ( U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Trends
7 Human Microbiome Market, By Disease
8 Human Microbiome Market, By Application
9 Market, By Product
10 Geographic Analysis
11 Competitive Landscape
12 Company Profiles
13 Appendix
Companies Mentioned:
- E. I. Du Pont De Nemours And Company
- Enterome Bioscience
- Merck & Co., Inc.
- Metabiomics Corporation
- Microbiome Therapeutics Llc.
- Osel Inc.
- Second Genome, Inc.
- Vedanta Biosciences
- Vithera Pharmaceuticals
- Yakult Honsha Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/plp27q/human_microbiome
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
SOURCE Research and Markets